The ICER for the European Association for the Study of the Liver (EASL) recommended HCC surveillance strategy (biannual US without AFP ($250/year) would become cost-effective at HCC incidence ≥ 0.39%/year (Fig 2C). Here, AFP is linked to hepatocellular carcinoma.